Charles River Laboratories International EBITDA 2011-2026 | CRL

Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.^[1]

EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.

EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.

However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.

Annual EBITDA Charles River Laboratories International

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
589 M	931 M	955 M	855 M	668 M	549 M	493 M	419 M	279 M	301 M	274 M	248 M	247 M	204 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
955 M	204 M	501 M

Quarterly EBITDA Charles River Laboratories International

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
219 M	220 M	195 M	-	206 M	238 M	211 M	-	230 M	243 M	245 M	-	226 M	264 M	224 M	-	224 M	206 M	185 M	129 M	192 M	134 M	152 M	109 M	145 M	129 M	115 M	102 M	128 M	120 M	101 M	62.8 M	108 M	113 M	102 M	69.1 M	92.9 M	90.4 M	76.1 M	52.3 M	79.3 M	78.9 M	65.4 M	40.8 M	72.2 M	75.3 M	59.8 M	24.6 M	108 M	83.6 M	62.8 M	-	98.3 M	89.3 M	63.7 M	-	101 M	96.4 M	63.5 M

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
264 M	24.6 M	131 M

References

Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.

EBITDA of other stocks in the Diagnostics research industry

Issuer	EBITDA	Price	% 24h	Market Cap	Country
Akumin AKU	70.1 M	-	-17.87 %	$ 25.9 M	Canada
Anixa Biosciences ANIX	-11.7 M	$ 3.11	-2.51 %	$ 101 K	USA
Centogene N.V. CNTG	-46 M	-	-6.23 %	$ 30.6 M	Germany
Accelerate Diagnostics AXDX	-12.3 M	-	-61.36 %	$ 2.46 M	USA
Brainsway Ltd. BWAY	-5 M	$ 22.32	-3.71 %	$ 99.4 M	Israel
BioNano Genomics BNGO	-90 M	$ 1.45	-3.67 %	$ 1.84 M	USA
Aspira Women's Health AWH	-32.5 M	-	-6.19 %	$ 10.5 M	USA
Burning Rock Biotech Limited BNR	-749 M	$ 30.5	-4.72 %	$ 328 M	China
Biocept BIOC	-30.3 M	-	-13.05 %	$ 7.29 M	USA
Check-Cap Ltd. CHEK	-25.8 M	-	-	$ 9.42 M	Israel
Castle Biosciences CSTL	24.7 M	$ 40.78	1.92 %	$ 1.13 B	USA
Co-Diagnostics CODX	-41.5 M	-	-	$ 79.8 M	USA
DexCom DXCM	784 M	$ 70.44	1.29 %	$ 27.2 B	USA
Oxford Immunotec Global PLC OXFD	-3.26 M	-	-	$ 562 M	Britain
Chembio Diagnostics CEMI	-21.1 M	-	0.22 %	$ 16.8 M	USA
Guardant Health GH	-401 M	$ 113.62	1.32 %	$ 13.9 B	USA
Global Cord Blood Corporation CO	652 M	-	-	$ 399 M	China
Fluidigm Corporation FLDM	-35.1 M	-	1.08 %	$ 308 M	USA
Genetic Technologies Limited GENE	-6 M	-	-	$ 7.1 B	Australia
Genetron Holdings Limited GTH	-518 M	-	0.12 %	$ 80.1 M	China
DermTech DMTK	-104 M	-	-11.32 %	$ 2.94 M	USA
PRA Health Sciences, Inc. PRAH	416 M	-	-	$ 10.7 B	USA
Illumina ILMN	-479 M	$ 147.36	4.03 %	$ 23.4 B	USA
CareDx, Inc CDNA	-189 M	$ 20.08	0.35 %	$ 1.08 B	USA
Danaher Corporation DHR	5.58 B	$ 234.95	-0.44 %	$ 172 B	USA
Celcuity CELC	-113 M	$ 105.63	-1.25 %	$ 4.17 B	USA
DarioHealth Corp. DRIO	-55.7 M	$ 12.48	0.28 %	$ 354 M	Israel
Enzo Biochem ENZ	-11.1 M	-	-8.98 %	$ 14.8 K	USA
Fulgent Genetics FLGT	-49 M	$ 27.65	-1.53 %	$ 836 M	USA
HTG Molecular Diagnostics HTGM	-20.2 M	-	-20.0 %	$ 1.06 M	USA
Exact Sciences Corporation EXAS	-757 M	$ 102.21	-0.22 %	$ 18.9 B	USA
Lantheus Holdings LNTH	522 M	$ 66.02	2.75 %	$ 4.57 B	USA
Medpace Holdings MEDP	475 M	$ 602.32	-1.41 %	$ 18.6 B	USA
IQVIA Holdings IQV	3.32 B	$ 234.18	-1.47 %	$ 42.5 B	USA
QIAGEN N.V. QGEN	301 M	-	-	$ 10.6 B	Niderland
Heska Corporation HSKA	-6.33 M	-	-	$ 1.31 B	USA
Neogen Corporation NEOG	-942 M	$ 9.28	0.27 %	$ 2.01 B	USA
National Research Corporation NRC	40.2 M	$ 22.06	-0.72 %	$ 541 M	USA
OPKO Health OPK	-53.9 M	$ 1.3	1.56 %	$ 902 M	USA
Pacific Biosciences of California PACB	-323 M	$ 2.36	6.79 %	$ 599 M	USA
Quest Diagnostics Incorporated DGX	1.84 B	$ 188.87	-0.33 %	$ 21 B	USA
Biodesix BDSX	-28.7 M	$ 8.85	12.25 %	$ 1.15 B	USA
Mettler-Toledo International MTD	50.4 M	$ 1 409.56	-3.5 %	$ 29.9 B	Schweiz
Laboratory Corporation of America Holdings LH	1.73 B	$ 272.02	0.42 %	$ 22.8 B	USA
ICON Public Limited Company ICLR	1.59 B	$ 176.57	-3.31 %	$ 14.6 B	Irlanda
IDEXX Laboratories IDXX	1.26 B	$ 688.67	-3.73 %	$ 56.8 B	USA
Myriad Genetics MYGN	-62.3 M	$ 5.65	-4.56 %	$ 512 M	USA
ENDRA Life Sciences NDRA	-10.8 M	$ 4.67	-2.3 %	$ 2.51 M	USA
Agilent Technologies A	1.67 B	$ 135.52	-2.95 %	$ 41.2 B	USA